Featured Research

from universities, journals, and other organizations

Persistence pays off in solving hemophilia mystery, showing curiosity drives discovery

Date:
March 7, 2013
Source:
University of New South Wales
Summary:
A medical researcher has found the third and final piece in the genetic puzzle of hemophilia B Leyden, more than 20 years after he discovered the first two pieces. The results explain how more than half of the cases of this rare blood-clotting disorder occur, could have implications for other conditions such as thrombosis and show the value of curiosity-driven research.

Professor Merlin Crossley is dean of science at University of New South Wales.
Credit: UNSW

An Australian researcher has found the third and final missing piece in the genetic puzzle of an unusual form of hemophilia, more than 20 year after he discovered the first two pieces.

Professor Merlin Crossley, of the University of New South Wales, and his international team studied the blood-clotting disorder, hemophilia B Leyden, which is unusual because symptoms improve after puberty.

The results, published in The American Journal of Human Genetics, explain how more than half of the cases of this rare, hereditary bleeding disorder occur, and could help improve understanding of other conditions such as thrombosis.

The find also demonstrates the importance of curiosity-driven research, says Crossley, who is dean of science at UNSW.

"Science is advanced by people who get caught up in puzzles that are important to them and they never forget them. Curious investigators never give up," he says.

Crossley spotted the final genetic clue two years ago, when he was on an aeroplane, marking a young researcher's PhD project. Data in the thesis reminded him of his own PhD project on hemophilia B Leyden, carried out at the University of Oxford in the late 1980s.

People with the disorder have three different categories of mutations in the gene that produces clotting factor IX, which prevents excessive bleeding. Crossley was able to work out how two of them operate, while at Oxford.

He found the two sets of mutations prevent two key proteins from attaching to the DNA, which turns the gene off as a result. Symptoms improve in young men after puberty because a different protein that responds to the hormone testosterone is able to bind to the DNA and boost the gene's production of clotting factor IX.

Crossley, and many other researchers after him, tried to find the key protein associated with the third group of mutations, which accounts for more than half the cases of the disease, but it remained elusive. "Things moved on, but I never forgot," he says.

Two decades later, on the plane, he realised the young researcher was describing a DNA-binding site for a newly discovered protein that had a very familiar ring to it. "I remembered it. It was the same sequence as for the binding site for the third group of mutations," Crossley says.

He joined forces with others at UNSW, including Dr Alister Funnell, and researchers in the UK, New Zealand and Belgium, to show the newly identified protein, ONECUT, was the missing piece in the puzzle of hemophilia B Leyden, which affects about 80 families worldwide.

The original research allowed families to be informed that their children were likely to get better after puberty.

While the new research will not alter the method of treatment for people with hemophilia B Leyden, it could lead to new approaches to regulating genes in general for experimental, or ultimately, therapeutic purposes.

"Understanding the molecular regulation of the coagulation factor IX gene may aid in the development of therapies for other blood-clotting disorders such as thrombosis," says Funnell.


Story Source:

The above story is based on materials provided by University of New South Wales. Note: Materials may be edited for content and length.


Journal Reference:

  1. AlisterP.W. Funnell, MichaelD. Wilson, Benoit Ballester, KaSin Mak, Jon Burdach, Natisha Magan, RichardC.M. Pearson, FredericP. Lemaigre, KathrynM. Stowell, DuncanT. Odom, Paul Flicek, Merlin Crossley. A CpG Mutational Hotspot in a ONECUT Binding Site Accounts for the Prevalent Variant of Hemophilia B Leyden. The American Journal of Human Genetics, 2013; 92 (3): 460 DOI: 10.1016/j.ajhg.2013.02.003

Cite This Page:

University of New South Wales. "Persistence pays off in solving hemophilia mystery, showing curiosity drives discovery." ScienceDaily. ScienceDaily, 7 March 2013. <www.sciencedaily.com/releases/2013/03/130307123949.htm>.
University of New South Wales. (2013, March 7). Persistence pays off in solving hemophilia mystery, showing curiosity drives discovery. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2013/03/130307123949.htm
University of New South Wales. "Persistence pays off in solving hemophilia mystery, showing curiosity drives discovery." ScienceDaily. www.sciencedaily.com/releases/2013/03/130307123949.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins